Vontobel Financial Products Gmbh (F06721) News

Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s QUELIMMUNE™ Therapy at Cincinnati Children’s

MINNEAPOLIS, July 26, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

Nuwellis Announces Pricing of $2.0 Million Offering Priced At-The-Market Under Nasdaq Rules

MINNEAPOLIS, July 24, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a...

Nuwellis, Inc. To Report Second Quarter 2024 Financial Results on August 13, 2024

MINNEAPOLIS, July 23, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company...

Form 8-K/A - Current report: [Amend]

Form 8-K - Current report

Nuwellis Marks First Commercial Sale of QUELIMMUNE™ Therapy to Cincinnati Children’s

MINNEAPOLIS, July 17, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company...

SeaStar Medical Ships First QUELIMMUNE Product Order to U.S. Distribution Partner

DENVER, July 12, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical...

Form EFFECT - Notice of Effectiveness

New Evidence on Aquadex Ultrafiltration Therapy to be Presented at HFSA 2024 Conference

MINNEAPOLIS, July 09, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. Nuwellis, Inc. (Nasdaq: NUWE), a medical...

Nuwellis Announces Reverse Stock Split

MINNEAPOLIS, June 26, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) (“Nuwellis” or the “Company”), a...

Nuwellis Secures New Patent for Innovative Pediatric Continuous Renal Replacement Therapy, Vivian™

MINNEAPOLIS, June 25, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company...

Form 8-K - Current report

Form 8-K - Current report